| NCT04126200 | GlaxoSmithKline | Multiple Myeloma | 2019-10-07 | PHASE1|PHASE2 |
| NCT04287855 | Poitiers University Hospital|Sanofi|Celgene|Amgen|Intergroupe Francophone du Myelome | Multiple Myeloma in Relapse|Multiple Myeloma, Refractory | 2020-08-28 | PHASE2 |
| NCT05911321 | UNC Lineberger Comprehensive Cancer Center|Genzyme, a Sanofi Company | Multiple Myeloma|Relapse|Refractory|Aging|Co-morbidity | 2023-12-05 | PHASE2 |
| NCT05137054 | Regeneron Pharmaceuticals | Multiple Myeloma | 2022-08-17 | PHASE1 |
| NCT04754945 | Emory University|Sanofi|National Cancer Institute (NCI) | AL Amyloidosis | 2021-04-28 | PHASE1 |
| NCT04802031 | Thomas Martin, MD | Relapsed Multiple Myeloma|Refractory Multiple Myeloma | 2021-05-28 | PHASE2 |
| NCT05346809 | Divaya Bhutani|Genzyme, a Sanofi Company | Lymphoma|Multiple Myeloma|Non-Hodgkin Lymphoma|Relapsed Hodgkin´s Disease, Adult | 2023-03-31 | PHASE2 |
| NCT03769181 | Sanofi | Lymphoma | 2018-12-11 | PHASE1|PHASE2 |
| NCT02283775 | Sanofi | Plasma Cell Myeloma | 2015-05-15 | PHASE1 |
| NCT05776979 | M.D. Anderson Cancer Center|Sanofi | Multiple Myeloma | 2023-08-17 | PHASE2 |
| NCT05559827 | Assistance Publique - H?pitaux de Paris | Immunological Pure Red Cell Aplasia | 2022-09 | PHASE2 |
| NCT04558931 | Karolinska Institutet|Sanofi|XNK Therapeutics AB, Sweden | Multiple Myeloma | 2021-06-02 | PHASE2 |
| NCT05405166 | Sanofi | Plasma Cell Myeloma Recurrent | 2022-06-23 | PHASE3 |
| NCT04850599 | OHSU Knight Cancer Institute|Oregon Health and Science University|Sanofi | Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma | 2022-06-14 | PHASE2 |
| NCT04751877 | Poitiers University Hospital|Intergroupe Francophone du Myelome|Sanofi | Multiple Myeloma|Myeloma | 2021-07-17 | PHASE3 |
| NCT04786028 | Canadian Myeloma Research Group | Multiple Myeloma | 2021-12-08 | PHASE2 |
| NCT03367819 | Sanofi | Prostate Cancer|Non-small Cell Lung Cancer | 2018-01-04 | PHASE1|PHASE2 |
| NCT05123131 | Cancer Trials Ireland|Sanofi|Dana-Farber Cancer Institute | Multiple Myeloma | 2022-04-01 | PHASE2 |
| NCT03104842 | Universit?tsklinikum Hamburg-Eppendorf | Multiple Myeloma | 2017-08-15 | PHASE2 |
| NCT04270409 | Sanofi | Plasma Cell Myeloma | 2020-06-16 | PHASE3 |
| NCT05669989 | Sanofi | Plasma Cell Myeloma | 2023-04-05 | PHASE2 |
| NCT05066607 | Intergroupe Francophone du Myelome|Sanofi|Bristol-Myers Squibb | AL Amyloidosis | 2022-02-11 | PHASE2 |
| NCT03319667 | Sanofi | Plasma Cell Myeloma | 2017-12-07 | PHASE3 |
| NCT05704049 | Sanofi | Relapsed+Refractory Multiple Myeloma | 2023-04-05 | PHASE2 |
| NCT03637764 | Sanofi | Neoplasm | 2018-08-06 | PHASE1|PHASE2 |
| NCT05804032 | University of Heidelberg Medical Center|Deutsche Studiengruppe Multiples Myelom (DSMM)|KKS Netzwerk|Sanofi | Multiple Myeloma | 2023-04-14 | PHASE3 |
| NCT05873205 | Memorial Sloan Kettering Cancer Center|Sanofi | Blood Cancer|Refractory Immune Cytopenias | 2023-07-21 | PHASE2 |
| NCT07217184 | GlaxoSmithKline | Multiple Myeloma | 2021-07-29 | PHASE1|PHASE2 |
| NCT06216158 | University of Heidelberg Medical Center|KKS Netzwerk|Wuerzburg University Hospital|Sanofi|Bristol-Myers Squibb | Multiple Myeloma | 2024-04-05 | PHASE3 |
| NCT06832865 | Massachusetts General Hospital|Pfizer|Sanofi | Relapsed Refractory Multiple Myeloma (RRMM)|Relapsed Refractory Multiple Myeloma | 2025-08-14 | PHASE2 |
| NCT05145400 | UNC Lineberger Comprehensive Cancer Center|Genzyme, a Sanofi Company | Multiple Myeloma|Cancer | 2022-02-18 | PHASE2 |
| NCT04835129 | Medical College of Wisconsin | Multiple Myeloma | 2022-01-10 | PHASE2 |
| NCT02812706 | Sanofi | Multiple Myeloma | 2016-09-05 | PHASE1|PHASE2 |
| NCT06762769 | University College, London|Sanofi|Bristol Myers Squibb Pharmaceuticals Limited | Smouldering Myeloma | 2025-06-02 | PHASE2 |
| NCT04653246 | Jacob Laubach, MD|Sanofi | Multiple Myeloma|Newly Diagnosed Multiple Myeloma (NDMM)|Autologous Stem Cell Transplant | 2021-07-13 | PHASE2 |
| NCT05298683 | Hellenic Society of Hematology|Sanofi | Multiple Myeloma|Renal Impairment|Neoplasms, Plasma Cell|Neoplasms by Histologic Type|Neoplasms|Paraproteinemias|Blood Protein Disorders|Hematologic Diseases | 2022-05 | PHASE2 |
| NCT04430894 | Massachusetts General Hospital|Amgen|Sanofi | Multiple Myeloma | 2020-07-10 | PHASE2 |
| NCT04483739 | European Myeloma Network B.V.|EMN Trial Office S.r.l. Impresa Sociale|Sanofi|Amgen | Multiple Myeloma | 2020-09-25 | PHASE3 |
| NCT05284032 | Firas El Chaer, MD | Platelet Refractoriness|Hematologic Malignancy | 2022-11-29 | EARLY_PHASE1 |
| NCT03194867 | Sanofi | Plasma Cell Myeloma | 2018-02-21 | PHASE1|PHASE2 |
| NCT04943302 | Tufts Medical Center|Sanofi | Amyloidosis|Light Chain (AL) Amyloidosis | 2022-09-01 | PHASE2 |
| NCT05114109 | Assistance Publique - H?pitaux de Paris | Multiple Myeloma|Monoclonal Gammopathy of Undetermined Significance|Cryoglobulinemic Vasculitis | 2021-11-01 | PHASE2 |
| NCT02332850 | Thomas Martin, MD|Amgen|Sanofi | Multiple Myeloma | 2015-01-21 | PHASE1 |
| NCT06119685 | Indapta Therapeutics, INC. | NHL|Multiple Myeloma|Blood Cancer|Refractory Non-Hodgkin Lymphoma|Relapsed Non-Hodgkin Lymphoma|Refractory Multiple Myeloma|Relapsed Multiple Myeloma | 2023-10-25 | PHASE1|PHASE2 |
| NCT06203912 | Elvira Umyarova|Sanofi | Recurrent Multiple Myeloma|Refractory Multiple Myeloma | 2024-03-05 | PHASE1 |
| NCT04458831 | Sanofi | Plasma Cell Myeloma | 2020-08-13 | |
| NCT07045909 | PETHEMA Foundation | De Novo Multiple Myeloma|Anitocabtagene Autoleucel | 2025-06-30 | PHASE2 |
| NCT04912427 | Washington University School of Medicine|Sanofi | Multiple Myeloma | 2022-04-01 | PHASE1 |
| NCT06517017 | University of Utah|Sanofi | Multiple Myeloma|Plasma Cell Leukemia | 2025-10-09 | PHASE2 |
| NCT04294459 | Sanofi | Immune System Disorder | 2020-06-18 | PHASE1|PHASE2 |
| NCT04934475 | Intergroupe Francophone du Myelome|Amgen|Sanofi|Bristol-Myers Squibb | Multiple Myeloma | 2021-12-08 | PHASE3 |
| NCT05862766 | NYU Langone Health | Antibody-mediated Rejection|Allosensitization | 2024-12-01 | EARLY_PHASE1 |
| NCT02513186 | Sanofi | Plasma Cell Myeloma | 2015-09-30 | PHASE1 |
| NCT03555149 | Hoffmann-La Roche | Colorectal Cancer | 2018-09-27 | PHASE1|PHASE2 |
| NCT04661033 | Sanofi | Warm Autoimmune Hemolytic Anemia (wAIHA) | 2021-09-09 | PHASE2 |
| NCT03989414 | Celgene | Multiple Myeloma | 2019-09-30 | PHASE1|PHASE2 |
| NCT04763616 | Won Seog Kim|Sanofi | Natural Killer+T-cell Lymphoma|Relapsed Natural Killer+T-cell Lymphoma|Refractory Natural Killer+T-cell Lymphoma | 2021-06-25 | PHASE2 |
| NCT07334535 | Peking Union Medical College Hospital|Handan Central Hospital|Inner Mongolia People´s Hospital|The Affiliated Hospital of Qingdao University|Hebei Medical University Third Hospital|North China University of Science and Technology|China-Japan Union Hospital, Jilin University|Cangzhou Central Hospital|Yantai Yuhuangding Hospital|Shengjing Hospital|Second Hospital of Shanxi Medical University|Beijing Chao Yang Hospital|Beijing Jishuitan Hospital|Henan Cancer Hospital|Beijing Hospital|Xuanwu Hospital, Beijing|Shandong Cancer Hospital and Institute | Multiple Myeloma | 2026-01-30 | PHASE4 |
| NCT03275285 | Sanofi | Plasma Cell Myeloma | 2017-10-25 | PHASE3 |
| NCT03499808 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Amorphous, Eosinophilic, and Acellular Deposit|Constipation|Diarrhea|Early Satiety|Gastrointestinal Hemorrhage|Hepatomegaly|Lymphadenopathy|Macroglossia|Nausea|Primary Systemic Amyloidosis|Purpura|Recurrent Primary Amyloidosis|Refractory Primary Amyloidosis | 2018-06-06 | PHASE2 |
| NCT05272826 | Canadian Myeloma Research Group | Multiple Myeloma | 2024-12-12 | PHASE2 |
| NCT06860269 | Assistance Publique - H?pitaux de Paris | Acute Lymphoblastic Leukemia | 2025-05-06 | PHASE2|PHASE3 |
| NCT07479979 | Natalie Callander|Sanofi|Karyopharm Therapeutics Inc|University of Wisconsin, Madison | Relapse Multiple Myeloma|Refractory Multiple Myeloma | 2026-07 | PHASE1|PHASE2 |
| NCT03530683 | Pfizer | Lymphoma|Multiple Myeloma|Acute Myeloid Leukemia|Diffuse Large B-Cell Lymphoma | 2018-05-14 | PHASE1 |
| NCT05147493 | Hellenic Society of Hematology|Sanofi | Multiple Myeloma|Renal Impairment|Neoplasms, Plasma Cell|Neoplasms by Histologic Type|Neoplasms|Paraproteinemias|Blood Protein Disorders|Hematologic Diseases | 2022-04 | PHASE2 |
| NCT06356571 | Sanofi | Plasma Cell Myeloma Refractory | 2025-03-17 | PHASE2 |
| NCT03733717 | Sanofi | Multiple Myeloma | 2018-10-22 | PHASE1 |
| NCT04083898 | Washington University School of Medicine|Sanofi | Multiple Myeloma | 2020-04-03 | PHASE1 |
| NCT05690984 | Medical College of Wisconsin | Multiple Myeloma | 2023-06-26 | PHASE2 |
| NCT06648889 | Goethe University|Sanofi | T-ALL | 2024-10-22 | PHASE2 |
| NCT04614558 | Columbia University|Genzyme, a Sanofi Company | Monoclonal Gammopathy | 2021-06-08 | PHASE2 |
| NCT01084252 | Sanofi | Hematological Malignancy | 2010-05-11 | PHASE1|PHASE2 |
| NCT04045795 | Sanofi | Multiple Myeloma | 2019-08-06 | PHASE1 |
| NCT05665140 | University Hopsital Schleswig Holstein Campus Lübeck | Newly Diagnosed Multiple Myeloma | 2023-02-03 | PHASE2|PHASE3 |
| NCT06182774 | Canadian Cancer Trials Group|Canadian Institutes of Health Research (CIHR)|Myeloma Canada | Multiple Myeloma | 2024-04-10 | PHASE3 |
| NCT02990338 | Sanofi | Plasma Cell Myeloma | 2016-12-22 | PHASE3 |
| NCT02999633 | Sanofi | T-cell Type Acute Leukemia-Precursor|T-lymphoblastic Lymphoma+Leukaemia | 2017-03-08 | PHASE2 |
| NCT05344833 | University of Illinois at Chicago|Huntsman Cancer Institute | Multiple Myeloma | 2023-01-05 | PHASE2 |
| NCT03860844 | Sanofi | Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia | 2019-08-06 | PHASE2 |
| NCT05558319 | PETHEMA Foundation|Bristol-Myers Squibb|Sanofi|Adknoma|Start from scratch | Newly Diagnosed Multiple Myeloma | 2022-10 | PHASE3 |
| NCT02514668 | Sanofi | Plasma Cell Myeloma | 2015-09-01 | PHASE1 |
| NCT04240054 | Medical College of Wisconsin | Multiple Myeloma | 2021-11-02 | PHASE2 |
| NCT01749969 | Sanofi | Plasma Cell Myeloma | 2013-02-06 | PHASE1 |
| NCT04939844 | Oslo University Hospital|Nordic Myeloma Study Group|St. Olavs Hospital|Helse Stavanger HF | Multiple Myeloma | 2021-06-29 | PHASE2 |
| NCT02960555 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Smoldering Plasma Cell Myeloma | 2017-02-08 | PHASE2 |
| NCT04643002 | Sanofi | Plasma Cell Myeloma Refractory | 2021-01-25 | PHASE1|PHASE2 |